Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison

Yoon K Loke; Shiva Pradhan; Jessica Ka-Yan Yeong; Chun Shing Kwok

doi:10.1111/bcp.12376

Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison

Yoon K Loke, Shiva Pradhan, Jessica Ka-Yan Yeong, Chun Shing Kwok

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.

Original language	English
Pages (from-to)	707–717
Number of pages	11
Journal	British Journal of Clinical Pharmacology
Volume	78
Issue number	4
Early online date	11 Mar 2014
DOIs	https://doi.org/10.1111/bcp.12376
Publication status	Published - Oct 2014

Keywords

acute coronary syndrome
apixaban
dabigatran

Access to Document

10.1111/bcp.12376

Cite this

@article{5829ff4c64584797a9a30c0adb79cdbf,

title = "Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison",

abstract = "There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.",

keywords = "acute coronary syndrome, apixaban, dabigatran",

author = "Loke, {Yoon K} and Shiva Pradhan and Yeong, {Jessica Ka-Yan} and Kwok, {Chun Shing}",

year = "2014",

month = oct,

doi = "10.1111/bcp.12376",

language = "English",

volume = "78",

pages = "707–717",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - Comparative coronary risks of apixaban, rivaroxaban and dabigatran

T2 - a meta-analysis and adjusted indirect comparison

AU - Loke, Yoon K

AU - Pradhan, Shiva

AU - Yeong, Jessica Ka-Yan

AU - Kwok, Chun Shing

PY - 2014/10

Y1 - 2014/10

N2 - There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.

AB - There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.

KW - acute coronary syndrome

KW - apixaban

KW - dabigatran

U2 - 10.1111/bcp.12376

DO - 10.1111/bcp.12376

M3 - Article

C2 - 24617578

VL - 78

SP - 707

EP - 717

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 4

ER -